UFP Technologies delivered higher sales in Q3 2025, but net income remained flat due to a $3 million labor-related expense. Adjusted EPS and revenue increased, driven by strength in the MedTech segment.
Q3 2025 revenue rose to $154.6 million, up from $145.2 million in Q3 2024.
Net income remained flat at $16.4 million despite top-line growth.
Adjusted EPS reached $2.39, up from GAAP EPS of $2.11.
MedTech sales grew 7.3%, while non-medical revenue declined 2.7%.
Management remains optimistic, citing progress on strategic initiatives and expected growth from new programs and acquisitions.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance